Wu's Battle: Suffering from multiple myeloma

Patient Wu, a 71-year-old male, was diagnosed with multiple myeloma. 

He sought treatment at Bioocus International Medical Center in 2022 and has been highly satisfied with his care. The initial pathology revealed lumbar MRI and T5T scan findings, including T10, T11, and L1 cone fractures with bone marrow edema. Additionally, small patchy abnormal signals were observed in the L2 vertebral body. A vertebral puncture biopsy confirmed plasma cell myeloma. Further examinations showed prokaryotic plasma comprising 46% of the bone marrow biopsy, with abnormal mounted cells constituting 14% in flow cytometry. Bone junction biopsy indicated 70% problastoma. FISH analysis revealed gene losses in lq21 (CKSIB) and 1m32 (CDKN2C), while the FTSH test was positive for p53 gene deletion, and ICH was negative in the FISH test. The final diagnosis was multiple osteoblastic follipoma (L light chain type), with DS staging in stage B group, ISS staging III, and RISS staging in Stage II. Patient Wu expressed gratitude for the comprehensive and personalized treatment provided by the medical center.

Previous treatment history:

The clinical manifestations of multiple myeloma are diverse, mainly including anemia, bone pain, renal insufficiency, infection, bleeding, neurological symptoms, hypercalcemia, and amyloid stools. The hospital conducted aggressive anti-infection treatment and corrected anemia and low platelets. About 2 months after BCMA CAR-T cell infusion, the patient's indicators gradually returned to normal, and his condition was under control. Bioocus International Medical Center has been continuously monitoring the patient to ensure the sustained stability of the treatment effects.